Name

MV-L

Recommended Name ?endolysin
Systematic Name ?peptidoglycan amidohydrolase
Alternative Name ?endolysin MV-L
phiMR11 lysin
acetylmuramoyl-alanine amidase
acetylmuramyl-alanine amidase
acetylmuramyl-L-alanine amidase
N-acetylmuramic acid L-alanine amidase
N-acetylmuramyl-L-alanine amidase
N-acetylmuramylalanine amidase
N-acylmuramyl-L-alanine amidase
peptidoglycan amidohydrolase
Uniprot IDQ08JW9
General Mode of ActionEnzymatic cleavage of peptidoglycan which results in a rapid lysis of the bacterial cell.
phiBIOTICS Family ?NAM amidase
Reaction ?1. Catalysis of the hydrolysis of the link between N-acetylmuramoyl residues and L-amino acid residues in certain bacterial cell-wall glycopeptides (R04112)
    EC: 3.5.1.28
    Corresponding Pfam domain: Amidase_2
    Evidence: predicted (PubMed: 17955443)
2. Catalysis of the hydrolysis of the bonds in cell wall peptidoglycans (amidohydrolase/peptidase activity)
    EC: n/a
    Corresponding Pfam domain: CHAP
    Evidence: predicted (PubMed: 17955443)
Source Organism ?Staphylococcus phage phiMR11
Target Organism ?Staphylococcus aureus
Staphylococcus simulans
Disease ?Infective endocarditis (Staphylococcus aureus)
Nosocomial infections (Staphylococcus aureus)
Osteomyelitis (Staphylococcus aureus)
Pneumonia (Staphylococcus aureus)
State ?Tested
Reference ?17955443


Studies found: 4

Antimicrobial Agent
Study Type
Model
Administration
Relevant ResultsAdverse Effects and Other IssuesReference ?
MV-L in vitro
  • set of Staphylococcus aureus strains including MRSA, MSSA, VRSA and VISA strains
  • other staphylococcal strains including:
    Staphylococcus epidermidis
    Staphylococcus mutans
    Staphylococcus simulans
  • diverse set of Gram-positive and Gram-negative bacterial strains
 Efficient lytic activity against all 13 S. aureus strains tested; 50 U of MV-L was sufficient to completely kill bacteria within the initial 15 min of exposure, moreover MRSA and MSSA strains were lysed with comparable efficiency.

Significant lytic activity against VRSA and VISA strains (some VISA strains were lysed only in non-growing conditions).

No lytic activity against the other staphylococcal strains; Gram-positive or Gram-negative bacterial species tested with exception for S. simulans.		 17955443
MV-L in vivo
  • murine model of nasal colonization
 intranasal

 Single dose of MV-L administered to mice 60 h after inoculation with MRSA resulted in complete elimination of bacterial colonization in 1 of 9 mice, substantial reduced colonization was observed in remaining 8 animals. Toxicity
Mice injected with lysin accumulated substantial levels of antibodies. Despite immunogenicity, mice that were repeatedly given lysin show no physical deterioration, also no abrogation of lysin activity was observed.		 17955443
MV-L in vivo
  • murine model of MRSA bacteremia
 intraperitoneal

 Single dose of lysin administered to mice 60 min after inoculation with lethal dose of MRSA resulted in therapeutic effect; 60% of treated animals were rescued (reducing the mortality rate to 40%). Administration of lysin simultaneously or 30 min after infection led to 100% survival of the mice. Toxicity
Mice injected with lysin accumulated substantial levels of antibodies. Despite imunogenicity, mice that were repeatedly given lysin show no physical deterioration, and also no abrogation of lysin activity was observed.		 17955443
MV-L + Vancomycin in vitro
  • VISA strain Mu50
Combination of MV-L (12.5-50 U) with VAN (4 µg/mL) resulted in synergistic effect against such VISA strain Mu50 with thickened cell wall, whereas either of agents alone failed to completely lyse Mu50 cells. 17955443